We report the case of a 10-year-old boy with congenital pure red cell aplasia (Diamond-Blackfan anaemia) who received an allogeneic bone marrow transplant (BMT) from his HLA-identical sister. The transplant was complicated by moderate veno-occlusive disease (VOD). Despite cytogenetic evidence of complete donor haemopoietic stem cell engraftment there was selective failure of red cell engraftment and he remains red cell transfusion-dependent. This is the first case of a stem cell transplant failing to correct the defect in this condition despite engraftment. Keywords: Diamond-Blackfan anaemia; bone marrow transplantation Diamond-Blackfan anaemia (DBA) is a congenital pure red cell aplasia usually presenting in the first year of life with profound normocytic or macrocytic anaemia, reticulocytopenia and marrow erythroblastopenia. It is a heterogenous condition with variable inheritance patterns, associated features and response to treatment.
Diamond-Blackfan anaemia (DBA) is a congenital pure red cell aplasia usually presenting in the first year of life with profound normocytic or macrocytic anaemia, reticulocytopenia and marrow erythroblastopenia. It is a heterogenous condition with variable inheritance patterns, associated features and response to treatment. 1 Although most cases are sporadic about 10% of cases are familial with either a dominant or recessive inheritance. Failure of spontaneous recovery and failure to demonstrate evidence of Parvovirus B19 distinguish DBA from transient erythroblastosis of childhood and red cell aplasia secondary to Parvovirus infection. Craniofacial anomalies, short stature and abnormalities of the thumb are the most commonly reported features. 2 The location of the abnormal gene has been mapped in some cases of dominantly inherited DBA to chromosome 19q23. 3 About 70% of cases are steroid-responsive and many of these will remain transfusion-independent although they often remain steroid-dependent. In vitro a variable response to cytokines such as IL-3, SCF, GM-CSF and human recombinant erythropoietin has been demonstrated. 4, 5 For patients who remain steroid-resistant the therapeutic options include regular transfusion therapy with chelation Correspondence: Dr RF Wynn, Royal Manchester Children's Hospital, Manchester, M27 4HA, UK Received 18 January 1999; accepted 13 May 1999 and stem cell transplantation. We report a case of failure of BMT to correct DBA, despite adequate engraftment.
Case report and methods
The patient presented at 3. weeks of age with pallor following Caesarean section for foetal distress. There was no family history of DBA. His height was below the third centile but no physical anomalies were present. Blood count showed a Hb 6.1 with slight macrocytosis and mild thrombocythemia. There was no evidence of granular lymphocytosis on the blood film. Bone marrow aspirate showed erythroblastopenia with otherwise normal marrow. ELISA analysis for Parvovirus B19 was negative.
He was transfusion-dependent from the age of 3 months and iron chelation, by subcutaneous desferrioxamine, was started at 20 months. There was no response to steroids or IL-3 and there were no red cell alloantibodies associated with red cell transfusion. Prior to BMT ferritin was recorded at 8200 g/l and liver biopsy showed marked iron deposition with no cirrhosis. Hepatitis and EBV serology was negative.
He was 10 years old on admission for bone marrow transplantation and the donor was his 7-year-old HLAidentical sibling. Brother and sister were ABO compatible with blood groups A and O, respectively. She had normal peripheral blood counts, reticulocyte count and marrow smear at the time of harvest. He was conditioned with busulfan 4 mg/kg in divided doses daily for 4 days and cyclophosphamide 50 mg/kg daily for 4 days. Graft-versus-host disease prophylaxis was with cyclosporine alone. At transplant he received 2.4 ϫ 10 8 nucleated cells/kg. Transplantation was complicated by moderate VOD at day ϩ13, which was managed conservatively and resolved completely. By day ϩ38 his neutrophil count was greater than 0.5 ϫ 10 9 /l and he was platelet independent from day +28. Despite engraftment he remained profoundly reticulocytopenic and marrow examination showed a marked reduction in erythroid precursors. An erythropoietin level was assayed and shown to be high. There was no evidence of red blood cell alloantibodies secondary to transfusion. There were markedly fewer clonogenic erythroid precursor cells in the post-BMT marrow in a standard CFUmix assay than in the donor marrow, assayed at the time of harvest. Addition of the patient's serum to normal bone marrow cultures did not reveal any inhibition of erythropoiesis. Using flow cytometry there was no evidence of glycophorin expression by CD34 ϩ cells. ELISA for Parvovirus B19 remained negative. Subsequently he has continued to require red cell transfusion with iron chelation despite either steroid or erythropoietin therapy.
Donor haemopoietic cell engraftment with complete stable cytogenetic chimerism of marrow and peripheral blood lymphocytes persist 2. years post-BMT. This has been demonstrated using conventional cytogenetic analysis of metaphases and by FISH analysis using a Y-chromosome probe.
Discussion
In this case report we demonstrate continuation of DBA phenotype despite engraftment of normal donor marrow. Successful correction of the defect has been reported since 1976 using stem cells from either umbilical cord or bone marrow. There are over 35 reported transplant recipients, including at least four umbilical cord blood transplants, of whom 24 are known long-term survivors without DBA. This experience is summarised in Table 1 . [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] DBA is clearly a heterogenous condition and we suggest that in a minority of patients allogeneic BMT will not correct the defect. This suggests either the presence of a stromal abnormality underlying the red cell defect in these cases or silent DBA of the donor. Recent advances such as genetic mapping 3 or evidence of elevated adenosine deaminase (ADA) 23 may provide further insight into the pathophysiology of DBA.
The decision to transplant a child with DBA depends upon an evaluation of balance of risks of transplant with those of chronic transfusion. We report this case so that it can form part of the pretransplant assessment and discussion about potential complications of BMT in this condition with parents.
